Psoriatic Arthritis News

Among patients with psoriatic arthritis who are biological-naive, apremilast monotherapy improved a variety of disease symptoms, including swollen, tender joints and morning stiffness, with no new safety concerns, according to findings from a phase 3b study published in the Annals of the Rheumatic Diseases.

A large number of patients with psoriatic arthritis and psoriasis are underdiagnosed and go without necessary treatment for hypertension and dyslipidemia, according to findings published in the Journal of Rheumatology.

Prevalence and incidence rates of psoriatic arthritis increased significantly in Taiwan from 2000 to 2013, while psoriasis exhibited no substantial change in incidence, according to findings published in the Journal of Rheumatology.

The Routine Assessment of Patient Index Data 3 for rheumatoid arthritis cannot be used in patients with psoriasis and psoriatic arthritis as it fails to account for potentially significant mental health considerations, according to findings published in the Journal of Clinical Rheumatology.

Rheumatology is a subspecialty in internal medicine and pediatrics that deals with the joints, soft tissues, autoimmune diseases and heritable connective tissue disorders. A rheumatologist specializes in the diagnosis, treatment and therapy of the rheumatic diseases.

In 2006, the European Medicines Agency approved Omnitrope, a biosimilar recombinant human growth hormone, as the first biosimilar. Over the subsequent decade, the EMA has approved additional biosimilars and, as of December 2017, 33 biosimilars were marketed in the European Union to treat a variety of conditions.

The FDA has approved Xeljanz for the treatment of adult patients with active psoriatic arthritis who have had an inadequate response or intolerance to methotrexate and disease-modifying antirheumatic drugs, according to a company press release.

The FDA has approved the third biosimilar to infliximab, infliximab-qbtx, for all eligible indications of the biologic product, according to a company press release.

SAN DIEGO — The American College of Rheumatology and the National Psoriasis Foundation have presented draft recommendations to be included in their new clinical guideline for the treatment of psoriatic arthritis, which is expected to be published in early 2018.

SAN DIEGO – Certain HLA alleles appear to safeguard against sacroiliitis among patients with psoriatic arthritis, while others may increase an individual’s likelihood of developing the condition, according to findings presented at the American College of Rheumatology Annual Meeting.